Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy or Observation After Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)~  * Mixed histology allowed if all components are consistent with NSCLC~ * Squamous cell histology allowed~* Stage IV disease~  * Oligometastatic disease (M1 with 1-3 metastases)~    * Patients with M1 disease that involves intrapulmonary metastases are eligible provided ≤ 40% of the total lung volume receives ≥ 20 Gy of radiotherapy~* Previously untreated disease OR achieved stable disease or partial response within 8 weeks after completion of 2-6 courses of standard platinum-based chemotherapy (administered every 3-4 weeks)~* Pleural effusion allowed provided it is minimal~* No history of or current brain metastases~  * Patients who have had up to 3 brain metastases allowed provided they have been treated with not signs of progression~PATIENT CHARACTERISTICS:~* ECOG performance status 0-1~* Life expectancy ≥ 12 weeks~* Platelet count ≥ 100,00/mm\^3~* Hemoglobin ≥ 9 g/dL~* WBC ≥ 2,000/mm\^3~* Creatinine ≤ 2 times upper limit of normal~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Able to undergo radiotherapy, based on radiation oncology consultation~* Willing and able to comply with study treatment~* FEV_1 ≥ 1 L~* No requirement for daily supplemental oxygen~* No second primary malignancy, except for any of the following:~  * Carcinoma in situ of the cervix~ * Nonmelanoma skin cancer~ * History of low-grade (Gleason score ≤ 6) localized prostate cancer, even if diagnosed within the past 5 years~ * Stage I breast cancer that was treated within the past 5 years~ * Other malignancy that was diagnosed and definitely treated ≥ 5 years ago with no subsequent evidence of recurrence~* No concurrent severe and/or uncontrolled medical condition, including any of the following:~  * Angina pectoris~ * Congestive heart failure within the past 3 months, unless LVEF \> 40%~ * Myocardial infarction within the past 6 months~ * Cardiac arrhythmia~* No clinically significant infection~* No psychiatric illness or social situation that would limit compliance with study requirements~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior therapy for this cancer other than 2-6 courses of standard platinum-based chemotherapy with or without bevacizumab~* No prior radiotherapy to the treatment sites (e.g., primary lesion, clinically involved nodes, or metastatic lesions)~* No bevacizumab during and for 4 weeks after completion of radiotherapy~* No concurrent systemic chemotherapy~* No other maintenance systemic therapy during radiotherapy~* No other concurrent investigational agents for the primary neoplasm~* No concurrent intensity modulated radiotherapy~* No concurrent prophylactic nodal radiotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: OTHER): Patients undergo observation for 6 weeks.
- Arm II (Type: EXPERIMENTAL): Patients undergo radiotherapy 5 days a week for 6 weeks to all sites of gross disease.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues